Pharmaceutical companies continue to provide financial support and funding for CME programs. Recently, these programs have come under scrutiny from numerous sources, including US Senator Grassley.
More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals.
On 8 June 2006, members and guests of the Pharma Marketing Roundtable met via conference call to discuss trends in commercial support of CME. This article summarizes that discussion.
Topics covered include:
- Will commercial (for-profit) CME providers and producers increasingly give way to academic center networks? Are the days of the large CME companies numbered?
- Which technological and media approaches for CME delivery are gaining favor...and which are losing ground?
- What role should CME play in strengthening the communicative skills of MDs in their interactions with patients? Why aren't we seeing more of this with the advent (peaks and valleys) of DTC?
Order and pay for this reprint now using your credit card...
Download PDF file immediately after paying: